Final clinical flashcards
Classes of antiarrhythmic drugs (5)
- Na+ blocking, membrane stabilising
- Beta blockers
- K+ channel blocking
- Non dihydropyridine CCBS
- Others
Class 1 antiarrhythmic drugs (3)
- Na+ blocking
- E.g lidocaine, propenafone, flecanide (split into further classifications)
- Contraindicated in asthma, copd, structural/IHD
Class 2 antiarrhythmic drugs (2)
- Beta blockers
2. Cardiospecific beta blockers: acebutol, atenolol, bisoprolol metoprolol, nebevilol
Class 3 antiarrhyhmic drugs (4)
- K+ channel blockers
- E.g. amiodarone, dronedarone, sotalol
- Amiodarone is 4 weeks before and 12 months after electrical cardioversion to increase success
- Dronedarone is associated with hepatotoxic and HF side effects
Class 4 antiarrhythmic drugs (4)
- Rate limiting CCBS (non-dihydropyridine)
- E.g verapamil, diltiazem
- Avoid verapamil in beta blocker pts (increased risk of hypotension and asystole)
- Diltiazem is unlicesned for arrhythmia
Class 5 antiarrhythmic drugs (3)
- Other
- E.g adenosine and digoxin
- Digoxin is only used if sedentary + AF+ congestive heart failure altogether
Maintenance treatment AF (2)
- Rate control is 1st line, rhythm control is 2nd line
2. Anticoagulation needed for stroke prophylaxis?
Rate control for AF (3)
- Beta blocker
- Rate limiting CCB
- Beta blocker+rate limiting CCB/ digoxin
Rhythm control for AF (2)
- Beta blocker
2. Sotalol/ amiodarone/ flecainide, propafenone, dronedarone
How to assess stroke and bleed risk in AF
- CHADsVASc and HASBLED
- Anticoagulate if chadvasc is 2 or more
- Consider further if HASBLED high risk of bleed 3 or more
CHADsVASc risk factors
Congestive HF HTN Age (75+) -2 Diabetes Stroke - 2 Vascular disease Age (65-74) Sex
HAS BLED risk factors
HTN Liver disease (bilirubin 2x normal and ALT etc 3x normla) Renal impairment Stroke history Bleeding history Labile INR Elderly Drugs (inc etoh)
If anticoagulation indicated in AF (as per chadvasc and hasbled)
If new onset give parenteral
If diagnosed, warfarin or DOAC
Amiodarone main indication
Treatment of arrhythmias, particularly when other drugs are ineffective or contraindicated
Amiodarone mode of action
K+ channel blocker. Prolongs the repolarization of the heart during phase 3 of the cardiac action potential, prolonging the length of the action potential.
Amiodarone side effects (8)
- Optic neuropathy (may cause blindness). Stop immediately if signs of impaired vision.
- Corneal microdeposits. May reverse on stopping. Cause night time glares when driving.
- Grey slated skin on exposure to sunlight (use wide spectrum, high SPF sunscreen for months after stopping)
- Phototoxicity.
- Peripheral neuropathy
- Pulmonary fibrosis, pneumonitis (SOB, cough)
- Hepatotoxicity. Watch out for nausea, vomiting, malaise, jaundice, itching, bruising, abdo pain.
- Thyroid issues (if hyper stop and give carbimazole, if hypo can continue and give levo)
Also commonly causes constpiatiom, movement disorders, sleep disorders, altered taste, vomiting
Amiodarone monitoring (5)
- K+ beforehand as may cause hypokalemia
- Chest x ray before
- TFTs before and then 6 monthly
- LFTs before and 6 monthly
- Annual eye tests (not in BNF)
+HR and BP as can cause hypotension and bradycardia
Amiodarone interactions (4)
Remember has a half life of around 50 days
- Enzyme inhibitors can increase the concentration of amiodarone e.g. grapefruit
- Amiodarone itself is an enyzme INHIBITOR and so increases the concentration of digoxin, warfarin and phenytoin (must half dose)
- Amiodarone increases the risk of myopathy and so avoid where possible. Manufacturer advises for simvastatin max 20mg OD with amiodarone/ amlodipine/ ranolazine/ verapamil/ diltiazem. (note max 40mg max for ticagrelor+simvastatin)
- Beta blockers and rate limiting CCBS can cause bradycardia, AV block and myocardial depression
- QT prolongation. Quinolone, macrolides, TCAs, SSRIs, lithium, quinine, hydroxychloroquinie, anti-malarials, antipsychotics
Drugs which prolong QT and therefore interact with amiodarone (9)
- TCAs
- SSRIs
- Lithium
- Quinine
- Quinolones
- Macrolides
- Hydroxychloroquinine
- Antimalarials
- Antipsychotics
Amiodarone: other
MHRA/CHM advice: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir (May 2015); simeprevir with sofosbuvir (August 2015): risk of severe bradycardia and heart block when taken with amiodarone (avoid but if necessary, counsel on signs of bradycardia and heart block)
Indications for digoxin (2)
- Maintenance for AF/ flutter (125-250)
2. Worsening/ severe heart failure in sinus rhythm (62.5-125)
Mode of action of digoxin
Digoxin induces an increase in intracellular sodium that will drive an influx of calcium in the heart and cause an increase in contractility. Cardiac output increases (positive inotrope) with a subsequent decrease in ventricular filling pressures. AV Node Inhibition: Digoxin has vagomimetic effects on the AV node. By stimulating the parasympathetic nervous system, it slows electrical conduction in the atrioventricular node, therefore, decreases the heart rate (negative chronotrope)
Bioavailability of digoxin preparations
Elixir 65%
Tablet 90%
IV 100%
BNF: “when switching from IV to oral route may need to increase dose by 20-33% to maintain the same plasma digoxin concentration)
Causes of digoxin toxiicty (4)
- Hypokalemia
- Hypomagnemesia
- Hypercalcemia
- Renal impairment